Sagimet Biosciences's net income is $-47M, below the sector sector average of $96M.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Loading...
Loading...
Sagimet Biosciences (SGMT) currently reports a net income of $-47M as of June 2026. That compares with $-59M in the prior-year period — up 20.7% year over year. That is below the sector sector average of $96M. Use the charts on this page to explore Sagimet Biosciences's net income history and peer comparisons.
Sagimet Biosciences's net income increased from $-59M to $-47M — a 20.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Sagimet Biosciences's net income of $-47M is lower than the its sector sector average of $96M. That is roughly 148.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Sagimet Biosciences reported $-47M in net income as of June 2026. That compares with $-59M in the prior-year period — up 20.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-47M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $96M. From there, open related valuation or income-statement pages for Sagimet Biosciences, and consider following SGMT for alerts when major investors trade the stock.